First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective

SIMPLE SUMMARY: Women and men have a different biomolecular profile that could impact drug utilization and survival in non-small cell lung cancer (NSCLC) patients. The aim of the study was to describe first-line pharmacotherapy and overall survival in non-resectable (nr)NSCLC patients by gender. Abo...

Descripción completa

Detalles Bibliográficos
Autores principales: Spini, Andrea, Gini, Rosa, Rosellini, Pietro, Singier, Allison, Bellan, Cristiana, Pascucci, Alessandra, Leoncini, Lorenzo, Mathieu, Clément, Martellucci, Ignazio, Furiesi, Folco, Giorgi, Silvano, Donnini, Sandra, Roberto, Giuseppe, Ziche, Marina, Salvo, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657179/
https://www.ncbi.nlm.nih.gov/pubmed/34885238
http://dx.doi.org/10.3390/cancers13236129
_version_ 1784612451301457920
author Spini, Andrea
Gini, Rosa
Rosellini, Pietro
Singier, Allison
Bellan, Cristiana
Pascucci, Alessandra
Leoncini, Lorenzo
Mathieu, Clément
Martellucci, Ignazio
Furiesi, Folco
Giorgi, Silvano
Donnini, Sandra
Roberto, Giuseppe
Ziche, Marina
Salvo, Francesco
author_facet Spini, Andrea
Gini, Rosa
Rosellini, Pietro
Singier, Allison
Bellan, Cristiana
Pascucci, Alessandra
Leoncini, Lorenzo
Mathieu, Clément
Martellucci, Ignazio
Furiesi, Folco
Giorgi, Silvano
Donnini, Sandra
Roberto, Giuseppe
Ziche, Marina
Salvo, Francesco
author_sort Spini, Andrea
collection PubMed
description SIMPLE SUMMARY: Women and men have a different biomolecular profile that could impact drug utilization and survival in non-small cell lung cancer (NSCLC) patients. The aim of the study was to describe first-line pharmacotherapy and overall survival in non-resectable (nr)NSCLC patients by gender. About 4400 incident cases of nrNSCLC were included. We reported a different use of target therapies on the basis of the known biomolecular profile between the two sexes. The survival improved in the last decade, and women and men also showed different survival if diagnosed with a squamous or non-squamous nrNSCLC. ABSTRACT: (1) Purpose: To describe first-line pharmacotherapy and overall survival in non-resectable non-small cell lung cancer (nrNSCLC) patients by gender. (2) Methods: Incident cases of nrNSCLC recorded between 2009 and 2019 (cohort entry) in the pathology registry of the regional administrative healthcare database of Tuscany were identified. Records of antineoplastic therapies delivered up to 4 months following cohort entry were classified as chemotherapy, target therapies, immunotherapies, and undefined monoclonal antibodies. First-line treatment and survival of patients receiving drug treatment was described. Analyses were stratified according to histology, gender, and cohort entry year. (3) Results: 4393 incident cases of nrNSCLC were included. Women with non-squamous-NSCLC received target-therapy more frequently than men (14.9% vs. 6.5%). Immunotherapy incidence of use varied between 3.8% (2017) and 9.1% (2019). The 2-year survival rate increased over time: for non-squamous-NSCLC, it was 22.3% (2009–2011) and 30.6% (2018–2019), while for squamous-NSCLC, it was 13.5% and 22.5%, respectively. After multivariate analysis, a low reduction in mortality risk in 2018–2019 vs. 2009–2011 was found (non-squamous: HR: 0.95 CI95%: 0.92–0.98; squamous: HR: 0.94 CI95%: 0.90–0.98). Among non-squamous NSCLC, median survival was longer in women than in men (389 vs. 276 days). (4) Conclusion: In light of sex-related biomolecular differences, among non-squamous NSCLC, women received target-therapy more frequently than men. Survival seemed to slightly improve over the study period for both histologies, despite a poor reduction in mortality risk was still observed.
format Online
Article
Text
id pubmed-8657179
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86571792021-12-10 First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective Spini, Andrea Gini, Rosa Rosellini, Pietro Singier, Allison Bellan, Cristiana Pascucci, Alessandra Leoncini, Lorenzo Mathieu, Clément Martellucci, Ignazio Furiesi, Folco Giorgi, Silvano Donnini, Sandra Roberto, Giuseppe Ziche, Marina Salvo, Francesco Cancers (Basel) Article SIMPLE SUMMARY: Women and men have a different biomolecular profile that could impact drug utilization and survival in non-small cell lung cancer (NSCLC) patients. The aim of the study was to describe first-line pharmacotherapy and overall survival in non-resectable (nr)NSCLC patients by gender. About 4400 incident cases of nrNSCLC were included. We reported a different use of target therapies on the basis of the known biomolecular profile between the two sexes. The survival improved in the last decade, and women and men also showed different survival if diagnosed with a squamous or non-squamous nrNSCLC. ABSTRACT: (1) Purpose: To describe first-line pharmacotherapy and overall survival in non-resectable non-small cell lung cancer (nrNSCLC) patients by gender. (2) Methods: Incident cases of nrNSCLC recorded between 2009 and 2019 (cohort entry) in the pathology registry of the regional administrative healthcare database of Tuscany were identified. Records of antineoplastic therapies delivered up to 4 months following cohort entry were classified as chemotherapy, target therapies, immunotherapies, and undefined monoclonal antibodies. First-line treatment and survival of patients receiving drug treatment was described. Analyses were stratified according to histology, gender, and cohort entry year. (3) Results: 4393 incident cases of nrNSCLC were included. Women with non-squamous-NSCLC received target-therapy more frequently than men (14.9% vs. 6.5%). Immunotherapy incidence of use varied between 3.8% (2017) and 9.1% (2019). The 2-year survival rate increased over time: for non-squamous-NSCLC, it was 22.3% (2009–2011) and 30.6% (2018–2019), while for squamous-NSCLC, it was 13.5% and 22.5%, respectively. After multivariate analysis, a low reduction in mortality risk in 2018–2019 vs. 2009–2011 was found (non-squamous: HR: 0.95 CI95%: 0.92–0.98; squamous: HR: 0.94 CI95%: 0.90–0.98). Among non-squamous NSCLC, median survival was longer in women than in men (389 vs. 276 days). (4) Conclusion: In light of sex-related biomolecular differences, among non-squamous NSCLC, women received target-therapy more frequently than men. Survival seemed to slightly improve over the study period for both histologies, despite a poor reduction in mortality risk was still observed. MDPI 2021-12-05 /pmc/articles/PMC8657179/ /pubmed/34885238 http://dx.doi.org/10.3390/cancers13236129 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Spini, Andrea
Gini, Rosa
Rosellini, Pietro
Singier, Allison
Bellan, Cristiana
Pascucci, Alessandra
Leoncini, Lorenzo
Mathieu, Clément
Martellucci, Ignazio
Furiesi, Folco
Giorgi, Silvano
Donnini, Sandra
Roberto, Giuseppe
Ziche, Marina
Salvo, Francesco
First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective
title First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective
title_full First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective
title_fullStr First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective
title_full_unstemmed First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective
title_short First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective
title_sort first-line pharmacotherapies and survival among patients diagnosed with non-resectable nsclc: a real-life setting study with gender prospective
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8657179/
https://www.ncbi.nlm.nih.gov/pubmed/34885238
http://dx.doi.org/10.3390/cancers13236129
work_keys_str_mv AT spiniandrea firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective
AT ginirosa firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective
AT rosellinipietro firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective
AT singierallison firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective
AT bellancristiana firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective
AT pascuccialessandra firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective
AT leoncinilorenzo firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective
AT mathieuclement firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective
AT martellucciignazio firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective
AT furiesifolco firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective
AT giorgisilvano firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective
AT donninisandra firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective
AT robertogiuseppe firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective
AT zichemarina firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective
AT salvofrancesco firstlinepharmacotherapiesandsurvivalamongpatientsdiagnosedwithnonresectablensclcareallifesettingstudywithgenderprospective